Rafferty Asset Management
CCCC icon

Rafferty Asset Management’s C4 Therapeutics CCCC Stock Holding History

Rafferty Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-143,855
Closed -$820K – 1146
2024
Q3 		$820K Sell
143,855
-41,883
-23% -$252K ﹤0.01% 838
2024
Q2 		$858K Sell
185,738
-647,943
-78% -$3.86M ﹤0.01% 848
2024
Q1 		$6.81M Buy
+833,681
New +$6.46M 0.03% 387
2023
Q1 		– Sell
-177,858
Closed -$1.05M – 1148
2022
Q4 		$1.05M Buy
177,858
+65,208
+58% +$541K 0.01% 741
2022
Q3 		$988K Buy
+112,650
New +$1.17M 0.01% 684
2022
Q2 		– Sell
-135,392
Closed -$3.29M – 1150
2022
Q1 		$3.29M Buy
135,392
+43,385
+47% +$1.05M 0.02% 487
2021
Q4 		$2.96M Buy
92,007
+32,956
+56% +$1.3M 0.02% 541
2021
Q3 		$2.64M Buy
59,051
+10,218
+21% +$438K 0.02% 547
2021
Q2 		$1.85M Buy
48,833
+1,927
+4% +$69K 0.01% 707
2021
Q1 		$1.74M Buy
+46,906
New +$1.87M 0.01% 661

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Rafferty Asset Management's CCCC Position: Q4 2024 in Review

Rafferty Asset Management sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 143,855 shares — an estimated $820K sold.

Rafferty Asset Management first reported a position in CCCC in Q1 2021 and held it in 10 quarters. The position peaked at $6.81M in Q1 2024. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Rafferty Asset Management reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 143,855 C4 Therapeutics shares in Q4 2024, an estimated $820K.
  • Rafferty Asset Management first reported a position in C4 Therapeutics in Q1 2021 and held it in 10 quarters.
  • Rafferty Asset Management's C4 Therapeutics position peaked at $6.81M in Q1 2024.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Rafferty Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.